Lung Cancer

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.

Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses RET rearrangements for patients with non–small cell lung cancer (NSCLC).

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.